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Abstract
Background: The purpose of this study was to advance a checklist of evaluative criteria designed to assess
patient-reported outcome (PRO) measures’ developmental measurement properties and applicability, which can be
used by systematic reviewers, researchers, and clinicians with a varied range of expertise in psychometric measure
development methodology.
Methods: A directed literature search was performed to identify original studies, textbooks, consensus guidelines,
and published reports that propose criteria for assessing the quality of PRO measures. Recommendations from
these sources were iteratively distilled into a checklist of key attributes. Preliminary items underwent evaluation
through 24 cognitive interviews with clinicians and quantitative researchers. Six measurement theory
methodological novices independently applied the final checklist to assess six PRO measures encompassing
a variety of methods, applications, and clinical constructs. Agreement between novice and expert scores
was assessed.
Results: The distillation process yielded an 18-item checklist with six domains: (1) conceptual model, (2) content
validity, (3) reliability, (4) construct validity, (5) scoring and interpretation, and (6) respondent burden and
presentation. With minimal instruction, good agreement in checklist item ratings was achieved between
quantitative researchers with expertise in measurement theory and less experienced clinicians (mean kappa 0.70;
range 0.66–0.87).
Conclusions: We present a simplified checklist that can help guide systematic reviewers, researchers, and clinicians
with varied measurement theory expertise to evaluate the strengths and weakness of candidate PRO measures’
developmental properties and the appropriateness for specific applications.
Abbreviations: PRO, Patient-reported outcome; FDA, Food and Drug Administration; HRQOL, Health-related quality
of life; COSMIN, COnsensus-based Standards for the selection of health Measurement INstruments; MID, Minimally
important difference; MPH, Masters of Public Health; PhD, Doctor of Philosophy; DrPH, Doctor of Public Health
Background
Improved health expectations have led to a shift away
from viewing health in terms of survival toward defining
as freedom from disease, followed by concentration on
an individual’s ability to perform daily activities, and
more recently to an emphasis on themes of well-being
and quality of life [1–4]. Concomitant to the evolving
conception of population health has been a transition
from reliance on clinically focused end points without
direct input from patients [5, 6] to increased emphasis
on patient-centered outcome research and comparative
effectiveness research [7]. As such, patients, families,
and clinicians are increasingly faced with complex
choices and ambiguous information when addressing
health and healthcare needs.
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It is important to differentiate between patient-
centered data and patient-centered outcomes. Data are
information deriving directly from patients, and out-
comes are end points that matter to patients [6, 7]. A
National Institutes of Health/Food and Drug Adminis-
tration (FDA) working group identified three categories:
feeling, function, and survival as primary patient-
centered outcomes to be focused on and incorporated
into all clinical trials proposing novel interventions, de-
vices, or pharmaceuticals that aim for FDA approval [5].
A significant challenge in patient-centered outcome re-
search and comparative effectiveness research is how
best to identify and use patient-centered outcomes that
measure effectiveness, facilitate decision-making, and in-
form health policy [8]. Patient-reported outcome (PRO)
measures are now commonly used in this capacity and
are defined as “any report on the status of a patient’s
health condition that comes directly from the patient,
without interpretation of the patient’s response by a clin-
ician or anyone else” [8, 9].
Nomenclature in this field is nuanced and PROs, PRO
measures, and health-related quality of life (HRQOL) are
often used interchangeably [10, 11]. Health-related qual-
ity of life is “the value assigned to duration of life as
modified by impairments, functional status, perceptions,
and social opportunities that are influenced by disease,
injury, treatment, or policy” [11–15]. In distinction,
PROs provide reports directly from patients about
health, quality of life, or functional status related to the
healthcare or treatment they have received [6, 16], and
PRO measures are designed to measure and report PRO
constructs [6, 17]. We have chosen to use the term
“PRO measure” heretofore to encompass the various
types of health-related instruments including HRQOL,
recognizing that others may prefer other terms [10, 16,
18]. Our rationale is that these types of instruments span
a diverse gamut that include symptom indices [19, 20],
general [21] and condition-specific HRQOL [22, 23],
utilities [24, 25], well-being [26, 27], or social health [28]
or can focus on latent constructs such as self-efficacy
[29] and willingness to change [30, 31].
Patient-reported outcome measures address the need
for patient-centered data and are now used in diverse
clinical, research, and policy pursuits [32]. Greater em-
phasis on patient-centered care has resulted in instru-
ment proliferation [33]. However, their developmental
rigor and intended application vary widely [34], and this
variation is likely to be reflected in systematic reviews.
For instance, these instruments can be used as outcomes
for group-level analyses in clinical trials and observa-
tional studies [35], but are also used to track within-
person change over time [36], for group-level quality im-
provement initiatives to provide information for report
cards [37], and as health surveys to monitor population
health [38, 39]. In practice, a specific measure may be
used in any or all these applications.
Patient-reported outcome measures have origins in
various measurement theory-related disciplines including
psychometrics [40], clinimetrics [41], and econometrics
[4]. There is considerable overlap in approach between
these disciplines, and collectively, they strengthen
quantitative design methodologies. The common core
principles of measure development are multifaceted
and sometimes complex. Identifying the appropriate
PRO measure for a particular purpose requires nuanced
understanding of a candidate measure’s underlying con-
ceptual model and its measurement properties [16].
Most clinicians, researchers, and patient advocates are
not experts in the technical methods used to develop
and validate these tools and may, understandably, pre-
sume similar performance among published PRO measures
that address a particular construct. This is problematic
since nearly all published tools purport some degree
of these attributes, most often as forms of reliability
or validity [34].
To address this issue, increased attention has been di-
rected toward understanding what defines adequacy
among PRO measures [5, 6, 10, 34, 42, 43]. This is
directly relevant to systematic reviewers choosing to in-
corporate PRO measures as outcomes for their reviews.
Current expert panel recommendations and proposed
criteria on this topic have substantial homology, but
differences do exist [6, 10, 34, 42–44]. Some advanced
criteria are not easily understood, and others are rigor-
ously prescriptive, tending to render most instruments
inadequate in several respects. These concerns have con-
tributed to disparate quality among systematic reviews
of PRO measures and have the potential to mislead re-
searchers into reliance on inappropriate or suboptimal
instruments for a given purpose [10, 45–47]. For ex-
ample, measurement bias in estimation of treatment
effects can occur due to lack of conceptual equivalence
between PRO measures [47].
An important and rigorous effort to aid researchers
in the selection of appropriate PRO measures, the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN), was devised be-
tween 2006 and 2010 by an expert panel with diverse
backgrounds (e.g., clinical medicine, biostatistics, psy-
chology, epidemiology) [11, 16, 44, 46, 48]. Consensus was
achieved as to measurement properties that should be
assessed and on criteria for acceptable measurement [11,
16, 44]. Three overarching measurement domains were
agreed upon: reliability, validity, and responsiveness. The
product of this important work was a detailed algorithm
for each identified domain. COSMIN remains the stand-
ard in the assessment of patient-reported outcome mea-
sures. However, its complexity (i.e., 119 items over 10
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categories) may limit its utility for a systematic reviewer,
researcher, or clinician who may not have expertise in
measurement theory. Furthermore, its stated use is for
evaluative instruments designed for applications to measure
change over time. It may not apply for discriminative
instruments, those used for predictive purposes, or
healthcare-related measures used to measure satisfac-
tion with care or adherence [16].
A simplified methodology that incorporates the critical
features highlighted in COSMIN and other pertinent
literature would be helpful to enable systematic reviewers,
researchers, and clinicians to assess developmental charac-
teristics and usefulness of a wide variety of PRO measures.
In addition, its usefulness would be enhanced by the in-
clusion of practical aspects of PRO measures not con-
sistently addressed in other criteria [6]. Thus, our study
aimed to (1) advance a set of simplified criteria, in the
form of a checklist, that can aid in systematically assessing
the measurement properties and usefulness of PRO mea-
sures for particular circumstances and 2) demonstrate the
checklist’s user-friendliness by determining the inter-rater
reliability of its scoring between clinicians/researchers
with and without expertise in empirical instrument devel-
opmental methods. The resultant checklist is intended as
a guide for systematic reviewers, researchers, and clini-
cians with diverse measurement theory expertise to aid in
identifying the strengths, weaknesses, and applicability of
candidate PRO measures.
Methods
A review of the literature was performed to identify
recommendations for evaluating PRO measures. The di-
rected search enabled the compilation of PRO measures’
developmental recommendations from a wide variety of
sources including the FDA [5, 6], the Scientific Advisory
Committee of the Medical Outcomes Trust [43, 49],
COSMIN [11, 16, 44, 46], Agency for Healthcare Re-
search and Quality [10], American Psychological Associ-
ation [50, 51], measurement theory textbooks [40, 52–54],
and individual studies via a PubMed search for evaluative
criteria germane to PRO measures, health-related quality
of life, and related terminology. This study did not involve
data collection from or about human subjects and was
therefore exempt from IRB review.
Two investigators (DOF, IDF) analyzed and synthesized
these recommendations and iteratively distilled them into
initial criteria. Attributes considered fundamental were (1)
conceptual model, (2) content validity, (3) reliability, (4)
construct validity, (5) scoring and interpretation, and (6)
respondent burden and presentation. Founded in psy-
chometrics (e.g., classical test and item response theories)
[40, 43, 55, 56] and clinimetrics [57], the core qualities
outlined below encompass the theoretical underpinnings
of a PRO measure and the developmental characteristics
necessary to ensure its overall usefulness.
1. Conceptual model provides a rationale for and
description of the concepts and the populations that
a measure is intended to assess [8, 43, 58, 59]. The
concept is the specific measurement goal and should
be explicitly stated in the development process.
Conceptual models are developed by outlining
hypothesized and potential concepts and
relationships and by determining the target
population and model’s application [6, 58, 60]. In
assessing its adequacy, a candidate measure’s original
development should be examined to determine if it
is likely to capture the intended effect [10]. Whether
multiple domains or subscales are expected should
be clearly inherent to or directly pre-specified within
the conceptual framework [8, 43, 61]. Ninety percent
of International Society for Quality of Life Research
survey respondents endorsed that PRO measures
should have documentation defining the construct
and describing the measure’s application in the
intended population [5, 8, 43].
2. Content validity refers to evidence that a PRO
measure’s domain(s) is appropriate for its intended
use in both relevance and comprehensiveness [10, 43,
46, 61, 62]. No formal statistical test exists to evaluate
content validity. Instead, assessment is done through
applying qualitative criteria. Specifically, items (i.e.,
questions) and conceptual domains (e.g., subscales)
should be relevant to target patients’ concerns. Thus,
developers should obtain input from the target
population to optimize item relevance and clarity,
ideally, through qualitative focus groups and cognitive
interviews [5, 61]. In brief, cognitive interviews are a
qualitative research tool used to determine whether
respondents understand included concepts and items
in the way that PRO measure developers intend.
These interactive “field-test” interviews allow
developers to better understand how respondents
interpret candidate questions [6]. Similarly, content
experts should participate in PRO measure
development with emphasis on evaluating the
relevance of items for the construct and for the
respondent population [43, 46, 61, 62], and there
should be a thorough description of how items were
elicited, selected, and developed [5].
3. Reliability is the degree to which scores are free from
random (measurement) error [11, 43]. Several forms
exist. Internal consistency reliability, the degree to
which segments of a test (e.g., split halves, individual
items) are associated with each other [56], reflects
precision at a single time point [43]. It is based on
correlation of scores between different items within
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the PRO measure, thus assessing whether items
proposed to measure the same general construct or
domain are statistically related. Test-retest reliability
refers to the reproducibility or stability of scores
over two administrations, typically in close temporal
proximity, among respondents who are assumed not
to have changed on the relevant domains [43, 56].
Traditionally cited minimum levels for reliability
coefficients are 0.70 for group-level comparisons and
0.90 to 0.95 for individual comparisons [8, 43].
Coefficients indicate the ratio of true score variance
to observed score variance. These thresholds are
important to establish the reliability of an instru-
ment. However, some argue that establishing
absolute thresholds for interpreting coefficients may
be overly prescriptive [8, 53]. Therefore, reliability
estimates lower than the convention cited above
should be justified in the context of the proposed
PRO measure’s intended application, its sample size,
and the reliability statistic used [63].
4. Construct validity refers to whether a test measures
theoretic intended constructs or traits [40, 43, 56],
and it directly affects the appropriateness of
measurement-based inferences. Evidence of con-
struct validity can derive from empirical demonstra-
tions of dimensionality [5, 55]. A variety of latent
variable modeling techniques such as factor analysis
are available to evaluate and provide evidence of
dimensionality, and these methods should be used
and reported when subscales or domains are
proposed or expected. Factor analysis (and related
latent variable methods) is, in general, a data reduc-
tion method intended to mathematically represent a
large number of differentially related questions (i.e.,
items) by a smaller number of latent dimensions or
“factors.” A factor is a mathematical representation of
a collection of variables that are statistically related to
one another, which differs conceptually from other
factors [53, 55]. Generally speaking, factor analysis
methods such as common factor analysis, principal
components analysis, and bi-factor analysis are
important in both classical and item response
theory-based instrument development processes [55].
Responsiveness to change, which is also known as
longitudinal construct validity [64], can be
considered an aspect of validity [65] or as a separate
dimension [11]. It is the extent to which a PRO
measure detects meaningful change over time when
it is known to have occurred [8, 43, 66]. Most, but
not all, instruments have a stated goal of measuring
change over time. Thus, this property is not
applicable to PRO measures intended specifically for
cross-sectional study designs. If a measure is not
intended to measure change (e.g., screening test),
this point should be specified in the conceptual
model. Responsiveness requires demonstrable
test-retest reliability and the ability to detect an
expected change (e.g., after intervention) in the
intended population [43, 66]. Absence of either
element limits the confidence that measured
differences in scores represent an actual change
rather than measurement error.
Responsiveness to change can be measured using
two approaches: distribution- or anchor-based
methods. Distribution-based methods are based on
either within-group change over time or between-
group comparisons. Such approaches are character-
ized by an effect size, standard response mean, or as
other measures that account for actual change
related to random error (e.g., standard error of
measurement) [10]. Anchor-based methods quantify
differences by examining the relationship between
the PRO measure score and an independent measure
(anchor) that could be patient-based, physician-based,
or an alternate external assessment of construct
severity [67–69]. Both methodologies necessarily
incorporate both expected change and test-retest
reliability in their calculation. Candidate PRO
measures’ responsiveness characteristics are
particularly relevant for systematic reviewers
aiming to compare effectiveness of interventions.
Another form of construct validity is the degree to
which PRO measure scores correlate with other
questionnaires that evaluate the same construct or
with related clinical indicators (e.g., pulmonary
function tests) [43, 56]. This is sometimes referred
to as “convergent validity.” A priori hypotheses
about expected associations between a PRO measure
and similar or dissimilar measures should be
documented [8, 43]. A closely related concept, called
“known groups” or divergent validity, requires the
PRO measure to differentiate between groups that
past empirical evidence has shown to be different.
These types of validity have also been classified
under the auspices of hypotheses testing [46].
It is rarely possible to establish a PRO measure’s
criterion validity because, in the majority of cases,
no “gold standard” exists to measure the targeted
construct [8]. It is, however, a pertinent parameter
in questionnaires designed to be predictive of a
certain state (predictive validity). For example, self-
rated health has been shown to predict mortality
[70]; thus, predictive validity can be considered a
form of criterion-related validity. A clear distinction
needs to be made between predictive and longitudinal
validity (responsiveness). The former refers to the abil-
ity of a “baseline” score (e.g., test result) to predict some
future event [53] and is reflected by that association. It
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does not imply a measure’s ability to distinguish change
between initial and follow-up assessments.
5. Scoring and interpretation. Interpretability is the
degree to which the meaning of scores is easily
understood [5, 8, 43, 71]. This requires that a scoring
system be clearly described and that some form of
scaling exists to indicate what different scores mean.
A scoring system defines how to compute scores,
whether as a total score or subscales, on the basis of
empirical evidence (e.g., a principal component
structure supporting a particular number of
subscales). Scaling properties depend on the context
of the measurement instrument. Total score and
item-level scaling are often used and several meth-
odologies exist, including those from classical test
theory (e.g., standard error of true scores) [55, 56]
and item response theory (e.g., Rasch modeling)
[55, 56]. Empirically based scaling allows end users
to readily interpret scores, as does considering the
availability of relevant population-level or condition-
specific normative data or “norms,” which permit
referencing scores to appropriate standards.
It is important to understand what represents a
minimally important difference and to have the
ability to differentiate degrees of difference (e.g.,
severity) for the construct [72]. Minimally important
difference (MID) is defined as “the smallest
difference in score in the outcome of interest that
informed patients or proxies perceive as important,
either beneficial or harmful, and that would lead the
patient or clinician to consider a change in
management” [73]. In brief, MID can be established
using distribution- or anchor-based approaches. The
anchor should be independently interpretable, and
there must be reasonable correlation between the
PRO measure score and anchor [72, 74]. The
distribution-based method uses the magnitude of
change compared to the variability in scores (e.g.,
effect size). A salient argument is also made that the
term “patient-important” is more appropriate than
“clinically important” to emphasize the patient-
centrism of these outcomes and the goals of directed
interventions [18, 75]. The meaningfulness of differ-
ences should ideally be based on what patients
consider a minimally important, small, moderate,
and large difference [76]. Incorporating patients’ per-
spective on what constitutes a difference strengthens
the clinical usefulness of the PRO measure. Without
this information, it can be difficult to contextualize
longitudinal or cross-sectional outcomes and under-
stand if the magnitude of change is important.
Finally, an often overlooked aspect of scoring and
interpretability is an explicit plan for managing and/
or interpreting missing responses [77], which are
common in the practical use of PRO measures
[78]. Missing item data introduces error in
individual score computation. Data that are
missing in a systematic manner may introduce
bias into group- and population-level analyses.
Several methods exist to manage missing responses
and data, and instructions regarding how to manage
missing responses are important. Without them, the
user is often left to score only those surveys for which
responses are complete.
6. Respondent burden and presentation. Burden refers
to the time, effort, and other demands placed on
respondents or those administering the instrument
[43, 71]. Acceptable burden in the context of the
number of items in and the time necessary to
complete a PRO measure is somewhat subjective
and depends on the measure’s intended use. Lengthy
measures might be considered reasonable in a
research setting but overly burdensome if
administered during a busy clinic. These issues
should be explicitly considered, as overly
burdensome PRO measures can limit their
applicability and practical adoption into studies [79].
The length of a PRO measure should be
contextually appropriate [71].
Another consideration of burden and presentation is
the literacy level required to understand and
complete the measure [80]. Most experts
recommend that items be at the sixth grade reading
level or lower; however, this criterion should be
contextualized to the intended target population [8]
and it should be justified. Finally, a PRO measure’s
items and their presentation should be available to
be viewed or accessed by persons considering
incorporating its use into practice [71]. Without this
level of transparency, it is difficult to fully evaluate a
prospective instrument’s appropriateness for a
particular application.
Cognitive interviews
Our goal of distilling key criteria into a checklist was to
provide guidance on how to systematically evaluate
candidate PRO measures’ developmental characteristics
and usefulness for a particular purpose. The intended
audience for the proposed criteria is systematic re-
viewers, researchers, and clinicians with varied expert-
ise in PRO measure development and application.
Thus, the initial criteria checklist was reviewed by a
group of 12 clinicians (medical students [n = 3], physi-
cians [n = 9]) and 12 investigators with expertise in
survey-based quantitative methods (MPH [n = 6], PhD/
DrPH [n = 6]). Each participant was asked to review
and comment on the clarity, accuracy, completeness,
and user-friendliness of the criteria. Study personnel
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asked respondents directed follow-up questions to fos-
ter discussion and further clarification of concerns.
Comments were used to improve clarity, readability,
accuracy, and completeness and to establish the revised
final criteria checklist (Fig. 1).
Inter-rater reliability of the checklist
Two investigators (DOF, IDF) used the checklist to
assess six pre-specified PRO measures encompassing a
variety of methods and applications related to voice and
swallowing disorders [81–86]. Two measures were de-
signed to measure handicap (VHI, VHI-10) [81, 82], and
one each was designed to measure health-related quality
of life (V-RQOL) [85], coping (VDCQ) [84], and activity
and participation (VAPP) [87] associated with voice dis-
orders. Another measure developed using item response
theory techniques focused on health-related quality of
life among patients with achalasia [86]. Discordances were
resolved with a modified Delphi technique, and agreed
upon criterion-level decisions and tallies provided refer-
ence values for each measure. A group of six clinicians
without expertise in measurement theory graded the six
PRO measures, and their agreement with reference
“scores” was summarized as the kappa statistic. An a
priori threshold for kappa was set at greater than 0.50 for
each PRO measures to demonstrate at least moderate
agreement. A stepwise process was used. Participating
clinicians were first provided with the checklist (Fig. 1)
and brief written descriptions of concepts being evaluated
(Additional file 1: Figure S1). Each independently scored
the PRO measures, and if kappa scores were inadequate,
participants were provided 15 min of individualized edu-
cation on the concepts followed by rescoring as necessary.
This process provided more in-depth information and de-




The cognitive interviews highlighted that several respon-
dents were concerned that the checklist mentioned technical
detail or sophisticated concepts that the average user would
not be familiar with (e.g., factor analysis, item response
theory). Responding to these concerns, an addendum was
created and appended (Additional file 1: Figure S1).
Respondents expressed concern that some criteria did
not have strict benchmarks for decision-making. An
example is “has the PRO construct been specifically de-
fined?” Supporting documentation was clarified to note
that these criteria are necessarily general (and somewhat
vague) due to their inherent subjectivity and absence of
specific standards. One respondent questioned whether
the target population’s demographic or clinical character-
istics should be defined, and several recommended
Fig. 1 Checklist to operationalize developmental characteristics and applicability of patient-reported outcome measures
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simplifying grammar and sentence structure. They unani-
mously questioned the propriety of summing the criteria
into a total score and felt that the individual criteria pre-
sented did not warrant uniform weights.
Some respondents also recommended removing strict
thresholds for interpreting reliability. Despite this rec-
ommendation, we opted to include them because they
represent important, accepted conventions, especially
since less experienced users need some guidance regard-
ing interpretation. Some respondents felt it would be help-
ful to parenthetically list types of reliability that should be
tested (e.g., test-retest reliability, internal consistency), and
some questioned whether testing dimensionality through
factor analysis or other quantitative approaches should be
classified as a component of reliability rather than validity.
While the characteristics of scales and the items compris-
ing them can be assessed for their internal consistency
reliability, we opted to present this concept in the con-
struct validity section, with the rationale that empirically
identified dimensions should reflect the conceptual do-
mains represented by the PRO measure.
Another characteristic that proved difficult for some
respondents related to responsiveness. This question re-
quired that the PRO measure demonstrate both test-
retest reliability and evidence of responsiveness to
change. The rationale for the prerequisite of test-retest
reliability was that if a PRO measure has not shown sta-
bility then evidence of responsiveness cannot be proven.
Several reviewers suggested splitting this question so
that it only takes into account responsiveness to change.
Others recommended using the term “changes over
time” rather than responsiveness or longitudinal validity.
Several persons recognized the subjectivity of asking
reviewers to assess whether the PRO measure length was
“reasonable.” Initially, an example length of 10 items was
included if no mention of burden was mentioned. How-
ever, most respondents felt that was too prescriptive and
that longer measures were not overly burdensome in
specific circumstances. There was also question whether
the ability to access the entire PRO measure really mat-
tered. All of these issues were carefully considered, and
many suggestions were incorporated in the final criteria.
Proposed checklist
Shown in Fig. 1 is the proposed criteria checklist for asses-
sing the development characteristics and utility of PRO
measures. Eighteen characteristics are to be scored dichot-
omously (present/absent) in six general domains: concep-
tual model (three items), content validity (three items),
reliability (two items), construct validity (four items), scor-
ing and interpretability (three items), and respondent
burden and presentation (three items). On the basis of
feedback from cognitive interviews and in consideration
of the stage of the instrument’s development, individual
characteristics and domains were not weighted. The final
criteria are referred to as a checklist and are intended as a
guide when selecting or evaluating PRO measure.
Agreement between novice users and reference scores
All six participating clinicians independently scored
the same six individual PRO measures (n = 36). Over-
all, the mean clinician kappa for the first iteration
(written instruction only) was 0.54 (range 0.35–0.63)
with 21/36 reviews meeting the a priori criterion of
kappa greater than 0.50. One clinician met the criter-
ion on all six PRO measures on the first attempt
(Table 1). Two participants met the threshold for 5/6,
and one each met the threshold for 3/6, 2/6, and 1/6
of tested PRO measures.
The five remaining participants each received brief
education on concepts and rescored the measures for
which agreement was below the criterion (n = 15). In the
second iteration, four of five participants achieved ad-
equate agreement on all measures (Table 1). One required
a second educational session, followed by rescoring, and
thereafter achieved adequate agreement on all PRO mea-
sures. The final mean kappa statistic for the clinicians was
0.70 (range 0.66–0.87; Table 1).
Discussion
We distilled existing consensus criteria into a checklist
that can be readily employed in systematic reviews that
aim to assess PRO measures’ developmental properties.
This checklist provides end users a means to evaluate the
appropriateness of PRO measures prior to applying them
Table 1 Interventions and novice reviewer agreement with reference scores
Reviewer Written Kappa (range) 1st teaching Kappa (range) 2nd teaching Kappa (range)
1 X 0.63 (0.50–0.82)
2 X 0.59 (0.25–0.77) X 0.66 (0.56–0.77)
3 X 0.34 (0.02–0.61) X 0.66 (0.56–0.82)
4 X 0.51 (0.27–1.00) X 0.72 (0.54–1.00)
5 X 0.64 (0.49–1.00) X 0.66 (0.51–1.00)
6 X 0.54 (0.09–0.85) X 0.65 (0.33–1.00) X 0.87 (0.68–1.00)
X indicates that this type of instruction was provided to the reviewer. First provided was written instructions followed by in-person teaching (teaching was ≤15 min).
Kappa scores: mean (range)
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for research or clinical purposes. The checklist’s strength
is the demonstration that, with minimal instruction, sys-
tematic reviewers, researchers, and clinicians with limited
PRO measure methodological expertise can apply it with
ratings that correlate highly with experts in instrument
development methodology.
There are long-standing discussions about what consti-
tutes quality among survey and test instruments that even
occur in the fields of psychology and education, where
measurement theory was initially developed and promul-
gated. An initial consensus statement in 1954 identified
the core qualities of survey development as dissemination,
interpretation, validity, reliability, administration and scor-
ing, scaling, and norms [50]. Social scientists, statisticians,
and health outcome researchers have refined and ad-
vanced these developmental methodologies; however, the
same principles first described still pervade consensus
statements and expert opinion in the fields of education,
social science, and healthcare.
Incorporation of PRO measures’ developmental method-
ology in healthcare has evolved rapidly with the emergence
of comparative effectiveness research and patient-centered
outcome research. Feinstein aptly described the foundation
of this important work stating that “assessment of health
status is important because improvements in symptoms,
other clinical problems, and functional capacity are usually
the main goals of patients in seeking care” [88]. Patient-
reported outcome measures are increasingly used to better
understand the perspectives of and to measure concepts
that matter to the patient [5]. Methodological experts in
PRO measures and survey design have disseminated several
consensus statements to guide appropriate development
and implementation of these measures [5, 8, 10, 43, 89].
Use of poorly developed PRO measures or those designed
for a purpose that differs from their use can have significant
implications and lead to distorted, inaccurate, or equivocal
findings [5, 47]. Measures should be chosen based on rele-
vance and their track record in the context of the proposed
study [10]. Therefore, it is incumbent upon researchers and
other end users to carefully consider a measure’s properties
and weigh its strengths and potential weaknesses before
implementing it in practice, clinical trials, quality improve-
ment initiatives, or population-level studies.
Simplified access to evaluation criteria should encour-
age easier and more careful vetting of candidate PRO
measures by potential end users. It can be applied to
evaluate a specific instrument’s characteristics or in the
performance of systematic reviews of PRO measures’ de-
velopmental properties. The complexity and prescrip-
tiveness of prior consensus guidelines on PRO measure
development may limit their practical application by sys-
tematic reviewers, researchers, and clinician end users
who are not expert in survey design and measurement
theory. To overcome this issue, we have advanced a
simple checklist for evaluating the adequacy of any sur-
vey or PRO measure. It cannot be over emphasized that
its contents are not intended to replace prior consensus
statements on this topic. Instead, it aims to distill and
harmonize homologous concepts that have been widely
recognized in published expert consensus statements.
Considerations and limitations
Our proposed checklist is not exhaustive. Psychometric
and clinimetric PRO measures’ development principles
are often complex, conceptually overlapping, and evolving
[90]. It is not possible to accommodate and incorporate all
parameters and circumstantial caveats within simple cri-
teria. One example is administrative burden (e.g., personnel
time needed to help patients complete questions), which
can affect the ease of application of a particular PRO
measure and was not explicitly addressed in the present
checklist. Further, it is important to recognize that the
fundamental principles of survey development exist on
a spectrum, are often interchangeable, and are not
necessarily discrete concepts. An example is respon-
siveness, which has been categorized as an aspect of
validity [64, 65] but also as its own domain [11]. Add-
itionally, because each checklist characteristic was de-
rived from broadly accepted core concepts in survey
methodology and measurement theory that by their
nature are not necessarily expected to correlate with
each other, the utility of latent variable methods such
as factor analysis are not applicable at this stage.
The relative importance of a specific measurement prop-
erty may vary substantially with the purpose and context of
a PRO measure’s use. As such, we do not recommend a
total score for this tool since this implies each item should
be weighted equally. Our analysis of inter-rater reliability of
ratings between novice and more experienced practitioners
of measurement theory was not intended to provide rigor-
ous evidence of the checklist’s completeness. Instead, this
preliminary analysis was performed to show that this simple
checklist was easy to apply and reliable even among those
with little expertise the field. The proposed system is
designed to serve as a guide to understand the strengths
and weaknesses and applicability of any particular survey or
PRO measure.
Conclusions
Systematic reviewers, researchers, and clinicians who are
considering using a particular PRO measure as an out-
come in the performance of or evaluating clinical trial
results need to be able to assess whether the instrument
used was appropriate for the intended use. The checklist
provides simplified criteria that can be used to assess
developmental properties and usefulness of a variety of
PRO measures by end users with a wide range of expert-
ise in measurement theory, psychometrics, or survey
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development. Our intent was not to replace the cur-
rently available comprehensive evaluative consensus
guidelines. Instead, we propose that these criteria serve
as a distilled and simplified version of characteristics
that constitute an adequately developed PRO measure.
Psychometricians, statisticians, measurement theory ex-
perts, econometricians, and clinicians have iteratively de-
veloped and discussed these properties over decades, in
a literature that encompasses an array of disciplines. Re-
finements and evolution of these techniques continue.
However, the general fundamentals remain the bedrock
on which these innovations build. Our criteria attempt to
summarize these foundational concepts into a user-friendly
checklist that will help end users with a variety of back-
grounds to identify the strengths and weaknesses of avail-
able PRO measures for their particular application.
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